

An AACR Special Conference on

Colorectal Cancer: Biology to Therapy

October 27-30, 2010

Loews Philadelphia Hotel

Philadelphia, Pennsylvania

Wednesday, October 27

7:00 p.m.-8:00 p.m. Opening Session
Commonwealth Hall

7:00 **Welcome and Opening Remarks**
Anil Rustgi
Abramson Cancer Center, University of Pennsylvania,
Philadelphia, PA

7:15 **Keynote Address**
**Colorectal cancer genomes and their implications for
basic and applied research**
Bert Vogelstein
Johns Hopkins University, Baltimore, MD

8:00 p.m.-9:30 p.m. Welcome Reception
Millennium Hall

Thursday, October 28

7:00 a.m.-8:00 a.m. Continental Breakfast
Millennium Hall

8:00 a.m.-10:00 a.m. Session 1: Intestinal Stem Cells
Commonwealth Hall

8:00 **Targeting dormant drug-resistant cancer stem cells**
Linheng Li, Stowers Institute for Medical Research, Kansas City, MO

8:30 ***In vitro* analysis of intestinal stem cells**
Calvin J. Kuo, Stanford University, Stanford, CA

9:00 Relationship of intestinal epithelial progenitor cells within the stem cell niche

Melissa Hirose Wong, Oregon Health and Science University, Portland, OR

9:30 STAT3 as a novel cancer therapeutic target in colorectal cancer stem cells*

Li Lin, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH

9:45 TNIK is a protein kinase essential for Wnt signaling and colorectal cancer growth*

Tesshi Yamada, National Cancer Center Research Institute, Tokyo, Japan

10:00 a.m.-10:30 a.m. Break

Commonwealth Foyer

10:30 a.m.-12:30 p.m. Session 2: Regulation of the Genome

Commonwealth Hall

10:30 Dampening of TGFbeta responses by Myc-regulated microRNAs: Implications for colon cancer angiogenesis

Andrei Thomas-Tikhonenko, University of Pennsylvania, Philadelphia, PA

11:00 Mismatch repair and colorectal cancer: Understanding pathogenic variants using yeast as a model system

Alison Gammie, Princeton University, Princeton, NJ

11:30 Towards a unified systems biology of colorectal carcinoma

Bruce J. Aronow, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

12:00 microRNA binding site polymorphisms and their impact on cancer risk, tumor biology, and outcome

Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT

12:30 p.m.-2:30 p.m. Poster Session A and Lunch

Millennium Hall

2:30 p.m.-4:30 p.m. Session 3: Genetics of Susceptibility

Commonwealth Hall

2:30 Contribution by predisposing genes to the etiology, diagnosis, and prevention of colorectal cancer

Albert de la Chapelle, The Ohio State University Comprehensive Cancer Center, Columbus, OH

3:00 DNA repair and susceptibility to colon cancer

Joanna L. Groden, The Ohio State University College of Medicine, Columbus, OH

*Indicates proffered presentation from selected abstracts.

- 3:30** **The interaction of environmental exposures, germline susceptibility, and somatic alterations on colorectal cancer risk and survival**
Charles S. Fuchs, Dana-Farber Cancer Institute, Boston, MA
- 4:00** **A genetic model for early-onset breast and colon cancer in African Americans***
Phillip Buckhaults, The Medical College of Georgia Cancer Center, Augusta, GA
- 4:15** **mir-21 causes resistance to 5-fluorouracil by inducing MSH2-MSH6 downregulation in colon cancer***
Nicola Valeri, The Ohio State University, Columbus, OH

Friday, October 29

- 7:00 a.m.-8:00 a.m.** **Continental Breakfast**
Millennium Hall
- 8:00 a.m.-10:00 a.m.** **Session 4: Inflammation and Tumor Microenvironment**
Commonwealth Hall
- 8:00** **Inflammatory mechanisms in colon tumorigenesis**
Michael Karin, University of California, San Diego, La Jolla, CA
- 8:30** **Gastrointestinal cancer and the tumor microenvironment**
Timothy C. Wang, Columbia University Medical Center, New York, NY
- 9:00** **Inflammatory mediators and their role in the progression of colorectal cancer**
Raymond N. DuBois, University of Texas MD Anderson Cancer Center, Houston, TX
- 9:30** **Polarity regulator Cdc42 in intestinal epithelium morphogenesis and tumorigenesis***
Ryotaro Sakamori, Rutgers, The State University of New Jersey, Newark, NJ
- 9:45** **Discovery of autoantibody targets in colorectal cancer by using phage microarrays***
Ignacio Casal, Centro de Investigaciones Biológicas, Madrid, Spain
- 10:00 a.m.-10:30 a.m.** **Break**
Commonwealth Foyer

*Indicates proffered presentation from selected abstracts.

10:30 a.m.-12:30 p.m. Session 5: Mouse Models of Intestinal Cancer

Commonwealth Hall

- 10:30** **Suppression of colon cancer metastasis by Aes through inhibition of notch signaling**
Makoto Mark Taketo, Kyoto University Graduate School of Medicine, Kyoto, Japan
- 11:00** **Mechanisms of crypt fission**
Thaddeus S. Stappenbeck, Washington University School of Medicine, St. Louis, MO
- 11:30** **Host genetic factors controlling development of flat colonic adenomas**
David W. Threadgill, North Carolina State University, Raleigh, NC
- 12:00** **From human cancer genome to flies: Multigenic models of metastatic colon cancer in drosophila***
Erdem Bangi, Mount Sinai Medical Center, New York, NY
- 12:15** **The effect of vitamin D receptor activation on β -catenin-regulated transcripts in mice with colonic inactivation of both APC alleles***
Marsha DeSmet, Purdue University, West Lafayette, IN

12:30 p.m.-2:30 p.m. Break (lunch on own) and Mentoring Lunch Groups

2:30 p.m.-4:30 p.m. Session 6: Advances in Diagnostics

Commonwealth Hall

- 2:30** **Genetic opportunities for preventing death from colon cancer**
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH
- 3:00** **Early detection of colorectal cancer using stool DNA: Is it ready for prime time?**
Nita Ahuja, Johns Hopkins Medical Institutes, Baltimore, MD
- 3:30** **DNA methylation markers: Implications for therapy?**
Stephen B. Baylin, Johns Hopkins School of Medicine, Baltimore, MD
- 4:00** **Next-generation stool DNA testing for detection of colorectal neoplasia: Early marker evaluation***
David A. Ahlquist, Mayo Clinic, Rochester, MN
- 4:15** **The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits tumor growth in a genetically engineered mouse model for sporadic colon cancer***
Kenneth E. Hung, Tufts Medical Center, Boston, MA

5:00 p.m.-7:00 p.m. Poster Session B and Reception

Millennium Hall

*Indicates proffered presentation from selected abstracts.

Saturday, October 30

- 7:00 a.m.-8:00 a.m. Continental Breakfast**
Millennium Hall
- 8:00 a.m.-10:00 a.m. Session 7: Imaging of the GI Tract**
Commonwealth Hall
- 8:00 Molecular imaging approaches to colorectal cancer**
Umar Mahmood, Massachusetts General Hospital, Boston, MA
- 8:30 Miniaturized confocal microscope for early detection of GI cancers**
Christopher H. Contag, Stanford University School of Medicine, Stanford, CA
- 9:00 Imaging colon cancer targets for therapy**
Wafik S. El-Deiry, University of Pennsylvania School of Medicine, Philadelphia, PA
- 9:30 Whole genomic sequencing of nine colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion***
Adam Bass, Dana-Farber Cancer Institute, Boston, MA
- 9:45 Genome-wide molecular and functional analysis identified LNX2 as a novel candidate gene involved in colorectal carcinogenesis***
Jordi Camps, National Cancer Institute, Bethesda, MD
- 10:00 a.m.-10:30 a.m. Break**
Commonwealth Foyer
- 10:30 a.m.-12:30 p.m. Session 8: Clinical Trials and Experimental Therapeutics**
Commonwealth Hall
- 10:30 Novel agents in early development for colorectal cancer: Approach to individualized therapy**
S. Gail Eckhardt, University of Colorado Denver School of Medicine, Denver, CO
- 11:00 Managing the interface between chemotherapy and targeted therapy in patients with colorectal cancer**
Richard M. Goldberg, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 11:30 Efficacy and toxicity of VEGF inhibitors: Predictive markers and biological insights**
Herbert I. Hurwitz, Duke University, Durham, NC

*Indicates proffered presentation from selected abstracts.

PROGRAM

- 12:00** **An unappreciated role for EGFR-RasGEF signals in colorectal cancer with oncogenic K-RasG12V?***
Philippe Depeille, University of California, San Francisco, CA
- 12:15** **Synergistic killing of colorectal cancer cells by oxaliplatin and the BH3-mimetic ABT-737 requires induction of Noxa by wildtype p53 and oncogenic RAS***
Onno Kranenburg, University Medical Centre Utrecht, Utrecht, The Netherlands

Departure

*Indicates proffered presentation from selected abstracts.